Skip to main content
. 2020 Sep 10;84(2):505–507. doi: 10.1016/j.jaad.2020.09.007

Table I.

Distribution and timing of severe acute respiratory syndrome coronavirus 2 polymerase chain reaction and coronavirus disease 2019 antibody test results in relation to dermatologic manifestations

Testing characteristic Chilblains/pernio
Nonchilblains/pernio
All dermatologic conditions, including pernio and nonpernio
No. of pernio patients No. of pernio patients with timing data Pernio onset to testing interval, median (IQR), days No. of nonpernio patients No. of nonpernio patients with timing data Nonpernio dermatologic symptom onset to testing interval, median (IQR), days No. of patients No. of patients with timing data Dermatologic symptom onset to testing interval, median (IQR), days
PCR testing
 PCR+ 23 5 8 (5–14) 185 62 6 (1–15) 208 67 6 (1–14)
 PCR– 134 58 14 (7–28) 27 10 9 (5–13) 161 68 14 (7–24)
SARS-CoV-2–positive antibody testing
 IgM+/IgG+ 1 1 14 1 1 14
 IgM+/IgG– 7 7 24 (23–28) 7 7 24 (23–28)
 IgM–/IgG+ 1 1 99 5 5 31 (14–32) 6 6 32 (14–35)
 IgM unknown/IgG+ 3 3 35 (25–40) 10 7 38 (14–46) 12 10 37 (25–40)
 Ig+ (isotype unknown) 1 1 10 3 3 60 (30–107) 5 4 45 (20–84)
SARS-CoV-2–negative antibody testing
 IgM–/IgG– 17 5 37 (21–42) 1 18 5 37 (21–42)
 IgM unknown/IgG– 35 16 38 (33–50) 2 2 14 (0–27) 37 18 36 (28–49)
 Ig- (isotype unknown) 11 6 34 (21–60) 11 6 34 (21–60)

IgM, Immunoglobulin M; IQR, interquartile range; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; +, positive; , negative; —, no cases reported.